Matthew Foster, MD (IMAGE) UNC Lineberger Comprehensive Cancer Center Caption Matthew Foster, MD, and his UNC Lineberger colleagues have used an experimental safety switch incorporated as part of a chimeric antigen receptor-modified T cell therapy (CAR-T) for an aggressive form of leukemia to quickly and effectively reduce the severity of a neurotoxic side effect caused by CAR-T therapy. Credit UNC Lineberger Comprehensive Cancer Center Usage Restrictions None License Licensed content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.